Antoni Ribas Selected Research

Melanoma (Melanoma, Malignant)

6/2022	STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.
1/2022	Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
1/2022	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
1/2022	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
1/2022	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
1/2022	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
1/2022	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
12/2021	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
11/2021	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
10/2021	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antoni Ribas Research Topics

Disease

252	Melanoma (Melanoma, Malignant) 06/2022 - 11/2002
212	Neoplasms (Cancer) 01/2022 - 02/2002
23	Disease Progression 01/2021 - 01/2010
16	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2007
8	Inflammation (Inflammations) 01/2022 - 05/2009
8	Exanthema (Rash) 01/2021 - 01/2008
8	Fatigue 01/2019 - 01/2010
7	Brain Neoplasms (Brain Tumor) 01/2021 - 05/2007
7	Fever (Fevers) 01/2019 - 07/2009
6	COVID-19 01/2022 - 11/2020
6	Diarrhea 01/2017 - 06/2007
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015 - 06/2011
5	Prostatic Neoplasms (Prostate Cancer) 12/2020 - 08/2008
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 07/2008
4	Nausea 05/2015 - 06/2011
4	Keratoacanthoma 01/2015 - 06/2011
4	Experimental Melanoma 11/2009 - 06/2005
3	Synovial Sarcoma (Synovioma) 01/2022 - 01/2017
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 08/2008
3	Infections 01/2021 - 07/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2020 - 06/2015
3	Leukemia 07/2019 - 11/2014
3	Pneumonia (Pneumonitis) 01/2019 - 08/2015
3	Neutropenia 08/2015 - 01/2010
3	Body Weight (Weight, Body) 06/2015 - 07/2013
3	Uveal melanoma 08/2014 - 01/2012
3	Liver Neoplasms (Liver Cancer) 12/2007 - 02/2002
3	Hepatocellular Carcinoma (Hepatoma) 12/2007 - 02/2002
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 12/2005
2	Wounds and Injuries (Trauma) 01/2021 - 01/2018

Drug/Important Bio-Agent (IBA)

54	VemurafenibIBA 10/2021 - 04/2010
45	pembrolizumabIBA 06/2022 - 07/2013
42	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2011
38	AntigensIBA 01/2022 - 11/2002
30	IpilimumabIBA 01/2022 - 11/2011
29	Immune Checkpoint InhibitorsIBA 01/2022 - 07/2013
29	dabrafenibIBA 01/2022 - 01/2011
25	trametinibIBA 01/2022 - 02/2013
21	AntibodiesIBA 01/2022 - 08/2006
20	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2003
20	tremelimumabIBA 01/2019 - 12/2005
19	Pharmaceutical PreparationsIBA 01/2021 - 01/2010
18	Peptides (Polypeptides)IBA 12/2020 - 02/2003
18	Monoclonal AntibodiesIBA 04/2016 - 12/2005
16	T-Cell Antigen Receptors (T-Cell Receptor)IBA 07/2019 - 11/2009
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
15	cobimetinibIBA 10/2021 - 08/2014
15	VaccinesIBA 01/2021 - 11/2002
14	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2003
14	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 06/2003
13	LigandsIBA 01/2021 - 08/2005
12	EpitopesIBA 10/2021 - 03/2003
11	Mitogen-Activated Protein KinasesIBA 12/2020 - 01/2012
11	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 07/2007
11	HLA-A*02:01 antigenIBA 05/2013 - 03/2003
10	CTLA-4 AntigenIBA 10/2020 - 12/2005
9	NivolumabIBA 01/2022 - 01/2015
9	Phosphotransferases (Kinase)IBA 01/2020 - 08/2011
8	B7-H1 AntigenIBA 01/2022 - 06/2015
8	InterferonsIBA 01/2021 - 06/2009
8	CytokinesIBA 01/2019 - 08/2006
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2003
6	Programmed Cell Death 1 ReceptorIBA 10/2021 - 01/2015
6	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 12/2016
6	Interleukin-2 (IL2)IBA 01/2020 - 09/2007
6	EnzymesIBA 01/2017 - 01/2009
5	Proto-Oncogene Proteins B-rafIBA 01/2016 - 09/2010
5	Monophenol Monooxygenase (Tyrosinase)IBA 05/2011 - 04/2008
4	Chimeric Antigen ReceptorsIBA 11/2021 - 09/2014
4	Interferon-gamma (Interferon, gamma)IBA 10/2021 - 09/2010
4	CateninsIBA 01/2020 - 06/2015
4	Immunoglobulin G (IgG)IBA 01/2019 - 07/2007
4	MART-1 AntigenIBA 01/2018 - 04/2008
4	Small Interfering RNA (siRNA)IBA 08/2014 - 04/2010
4	Temozolomide (Temodar)FDA LinkGeneric 02/2013 - 07/2007
3	spartalizumabIBA 01/2022 - 10/2020
3	Cancer VaccinesIBA 01/2019 - 10/2007
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2018 - 07/2012
3	PolymersIBA 01/2018 - 03/2013
3	TAK 733IBA 01/2017 - 04/2012
3	Transcription Factors (Transcription Factor)IBA 02/2015 - 01/2009
3	Dihydrotachysterol (AT 10)IBA 05/2014 - 05/2008
3	PLX 4720IBA 03/2013 - 04/2011
3	Protein Kinases (Protein Kinase)IBA 02/2013 - 04/2010
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2011 - 02/2006
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2007 - 12/2003
2	Circulating Tumor DNAIBA 01/2022 - 11/2018
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022 - 10/2010
2	Death Domain ReceptorsIBA 01/2022 - 01/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 05/2009
2	Toll-Like Receptor 9IBA 12/2021 - 10/2018
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2021 - 12/2020
2	COVID-19 VaccinesIBA 11/2021 - 01/2021
2	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2021

Therapy/Procedure

145	Therapeutics 06/2022 - 08/2004
88	Immunotherapy 06/2022 - 02/2002
16	Drug Therapy (Chemotherapy) 01/2018 - 01/2010
5	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2020 - 01/2014
3	Injections 01/2018 - 08/2004
3	Biological Therapy 11/2014 - 12/2008